SLS लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 01:30):

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...

Stats
आज की मात्रा	534 130
औसत मात्रा	1.58M
बाजार मूल्य	76.24M
EPS	$0 ( 2024-03-28 )
अगली कमाई की तारीख	( $-0.210 ) 2024-05-09
Last Dividend	$0.420 ( 2010-12-09 )
Next Dividend	$0 ( N/A )
P/E	-0.990
ATR14	$0.00600 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Stergiou Angelos M.	Buy	159 000	Common Stock
2024-01-22	Stergiou Angelos M.	Buy	238 500	Stock Option (Right to Buy)
2024-01-22	Scheinberg David A	Buy	6 000	Common Stock
2024-01-22	Scheinberg David A	Buy	10 000	Stock Option (Right to Buy)
2024-01-22	Wood Barbara A	Buy	35 000	Common Stock

INSIDER POWER
95.64
Last 98 transactions
Buy: 3 194 450 \| Sell: 76 679

मात्रा सहसंबंध

लंबा: 0.10 (neutral)

छोटा: 0.88 (strong)

Signal:(56.833) Same movement expected

Sellas Life Sciences सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
GOODM	0.893
SINO	0.882
RMRM	0.84
XOG	0.835
ENER	0.835
ICON	0.826
IINN	0.813
SSIC	0.812
PMBC	0.808
BWMX	0.808

10 सबसे अधिक नकारात्मक सहसंबंध
CVRX	-0.88
SFST	-0.878
FXNC	-0.876
PDCO	-0.874
AIRS	-0.868
BDSX	-0.866
COMM	-0.852
TBNK	-0.849
UTME	-0.848
REKR	-0.843

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Sellas Life Sciences सहसंबंध - मुद्रा/वस्त्र

0.39
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.58
( weak negative )

Sellas Life Sciences वित्तीय

Annual	2023
राजस्व:	$0
सकल लाभ:	$0 (0.00 %)
EPS:	$-1.340

FY	2023
राजस्व:	$0
सकल लाभ:	$0 (0.00 %)
EPS:	$-1.340

FY	2022
राजस्व:	$1.00M
सकल लाभ:	$900 000 (90.00 %)
EPS:	$-2.10

FY	2021
राजस्व:	$0.00
सकल लाभ:	$-200 000 (0.00 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Sellas Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sellas Life Sciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.150	2010-09-09
Last Dividend	$0.420	2010-12-09
Next Dividend	$0	N/A
Payout Date	2010-12-20
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.570	--
Avg. Dividend % Per Year	0.00%	--
Score	1.52	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-08-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0.570	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-5.80	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-23.94	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.231	0.800	-3.85	-3.08	[1 - 3]
quickRatioTTM	0.191	0.800	-3.58	-2.86	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0473	-0.0710	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	154.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
freeCashFlowPerShareTTM	-1.242	2.00	-0.621	-1.242	[0 - 20]
debtEquityRatioTTM	-0.114	-1.500	-0.454	0.682	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-34.67	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.91

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.115	1.000	-0.214	0	[1 - 100]
returnOnEquityTTM	-23.94	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.242	2.00	-0.414	-1.242	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0326	1.500	-3.12	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.887

Sellas Life Sciences

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

के लिए वास्तविक समय के अद्यतन Sellas Life Sciences [SLS]

Upcoming Earnings Alert

Sellas Life Sciences Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)